Form 4: Plus Therapeutics Director Howard Clowes Acquires Stock Options

Director Howard Clowes acquired stock options in Plus Therapeutics, Inc. on February 18, 2025.

Summary

• On February 18, 2025, Howard Clowes, a director of Plus Therapeutics, Inc., acquired 40,122 stock options.
• The options have an exercise price of $1.18.
• The options vest monthly over 12 months from the grant date, or in full at the 2026 Annual Stockholder Meeting, subject to continued service.
• The expiration date for these options is February 17, 2035.
• Following the transaction, Clowes directly owns 40,122 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition. It could be slightly positive as it indicates insider confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reporting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, PSTV, Plus Therapeutics, beneficial ownership, Form 4